This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
ang ii | 548 |
angiotensin ii | 451 |
converting enzyme | 439 |
angiotensin system | 263 |
blood pressure | 161 |
acute respiratory | 132 |
ace inhibitors | 107 |
smooth muscle | 95 |
type receptor | 95 |
lung injury | 93 |
ii type | 92 |
ang i | 92 |
angiotensin converting | 91 |
respiratory syndrome | 89 |
severe acute | 86 |
ii receptor | 85 |
growth factor | 84 |
cardiovascular disease | 83 |
heart failure | 80 |
receptor blockers | 78 |
coronavirus disease | 75 |
amino acid | 74 |
oxidative stress | 73 |
ace expression | 72 |
mas receptor | 68 |
angiotensin receptor | 68 |
angiotensin i | 63 |
ace activity | 62 |
epithelial cells | 62 |
brain ras | 61 |
novel coronavirus | 61 |
spike protein | 60 |
severe critical | 57 |
diabetic nephropathy | 56 |
protein kinase | 55 |
gut microbiota | 55 |
podocyte injury | 55 |
ace gene | 54 |
plasma membrane | 53 |
acei arb | 52 |
vascular smooth | 52 |
endothelial cells | 52 |
renin receptor | 52 |
ras inhibitors | 51 |
respiratory distress | 50 |
muscle cells | 49 |
amino acids | 48 |
enzyme inhibitors | 48 |
distress syndrome | 47 |
ace ang | 46 |
angiotensinconverting enzyme | 44 |
renin angiotensin | 44 |
myocardial infarction | 43 |
syndrome coronavirus | 42 |
diabetes mellitus | 42 |
gene expression | 42 |
sars coronavirus | 42 |
animal models | 42 |
endothelial dysfunction | 41 |
nitric oxide | 39 |
high glucose | 39 |
kidney disease | 38 |
aldosterone system | 38 |
ang iii | 37 |
local ras | 37 |
ace inhibitor | 37 |
aceis arbs | 36 |
lung cancer | 36 |
human ace | 36 |
neutral endopeptidase | 36 |
type diabetes | 35 |
hypertensive rats | 35 |
vascular endothelial | 35 |
deficient mice | 35 |
hypertensive patients | 34 |
ace deficiency | 34 |
ras activation | 33 |
cord uid | 33 |
doc id | 33 |
nervous system | 32 |
signal transduction | 32 |
angiotensin type | 32 |
adipose tissue | 31 |
receptor antagonist | 31 |
classical ras | 31 |
activated protein | 31 |
blood flow | 30 |
host cells | 30 |
ang iv | 30 |
important role | 30 |
ace receptor | 30 |
oxygen species | 30 |
reactive oxygen | 30 |
acute lung | 30 |
mrna expression | 30 |
severe covid | 30 |
bone marrow | 29 |
protein expression | 29 |
clinical trials | 29 |
ace ace | 29 |
transgenic mice | 29 |
spontaneously hypertensive | 28 |
ras proteins | 28 |
ras components | 28 |
renal injury | 28 |
clinical characteristics | 28 |
may also | 27 |
mas axis | 27 |
induced lung | 27 |
tissue ras | 27 |
fusion proteins | 26 |
transmembrane domain | 26 |
cytokine storm | 26 |
lung tissue | 26 |
risk factors | 26 |
kidney injury | 26 |
central nervous | 25 |
inflammatory cytokines | 25 |
ras blockade | 25 |
disease severity | 25 |
necrosis factor | 25 |
map kinase | 25 |
ace shedding | 25 |
senescent cells | 25 |
endoplasmic reticulum | 24 |
system inhibitors | 24 |
cell growth | 24 |
systematic review | 24 |
er stress | 24 |
renin activity | 23 |
ras wt | 23 |
signaling pathway | 23 |
cardiovascular diseases | 23 |
ras system | 23 |
ii levels | 23 |
transforming growth | 23 |
lung tumor | 23 |
cell death | 23 |
reninangiotensin system | 23 |
infected patients | 23 |
factor receptor | 22 |
cell entry | 22 |
crucial role | 22 |
viral entry | 22 |
recombinant human | 22 |
signaling pathways | 22 |
receptor blockade | 22 |
ace levels | 22 |
critical outcomes | 22 |
ace axis | 22 |
arb users | 22 |
clinical outcomes | 22 |
increased ace | 22 |
trabecular bone | 22 |
cardiac hypertrophy | 22 |
active site | 22 |
enzyme inhibitor | 21 |
tumor cells | 21 |
receptor blocker | 21 |
ras pathway | 21 |
functional receptor | 21 |
molecular mechanisms | 21 |
viral infection | 21 |
increased risk | 21 |
immune responses | 21 |
coronavirus infection | 21 |
ace protein | 21 |
tumor necrosis | 21 |
insulin resistance | 21 |
gastrointestinal tract | 21 |
beneficial effects | 20 |
epidermal growth | 20 |
circulating ras | 20 |
hepatic fibrosis | 20 |
diabetic rats | 20 |
host cell | 20 |
prorenin receptor | 20 |
binding domain | 20 |
intensive care | 20 |
ace mrna | 20 |
cell proliferation | 20 |
virus infection | 20 |
orx mice | 20 |
cohort study | 19 |
liver disease | 19 |
ii receptors | 19 |
pulmonary hypertension | 19 |
liver fibrosis | 19 |
receptor mas | 19 |
united states | 19 |
severe disease | 19 |
tumor cell | 19 |
protective effects | 19 |
therapeutic target | 19 |
renal disease | 19 |
left ventricular | 18 |
protective role | 18 |
provided adjusted | 18 |
blood vessels | 18 |
immune system | 18 |
tumor tissue | 18 |
significantly reduced | 18 |
portal pressure | 18 |
cardiovascular system | 18 |
immune response | 18 |
cellular senescence | 18 |
enzyme inhibition | 18 |
cleavage site | 17 |
coupled receptor | 17 |
vsmc senescence | 17 |
basement membrane | 17 |
higher levels | 17 |
type i | 17 |
patients infected | 17 |
receptor axis | 17 |
human coronavirus | 17 |
collecting duct | 17 |
ras blockers | 17 |
chronic kidney | 17 |
tissue injury | 17 |
angiotensin receptors | 17 |
clinical studies | 17 |
alveolar epithelial | 17 |
ace inhibition | 17 |
podocyte apoptosis | 17 |
vascular senescence | 17 |
novel therapeutic | 16 |
control group | 16 |
critical illness | 16 |
integral membrane | 16 |
early dn | 16 |
increased expression | 16 |
mouse model | 16 |
cardiac dysfunction | 16 |
normal lung | 16 |
also known | 16 |
receptor signaling | 16 |
renal function | 16 |
knockout mice | 16 |
fatty acids | 16 |
proteolytic cleavage | 16 |
among patients | 16 |
rat model | 16 |
endothelial growth | 15 |
dm group | 15 |
sex differences | 15 |
membrane protein | 15 |
portal hypertension | 15 |
gene polymorphisms | 15 |
gender differences | 15 |
rat brain | 15 |
developing severe | 15 |
acute kidney | 15 |
coronavirus spike | 15 |
inflammatory response | 15 |
essential hypertension | 15 |
ectodomain shedding | 15 |
protective effect | 15 |
glomerular filtration | 15 |
serum potassium | 15 |
senescence via | 15 |
potential therapeutic | 15 |
cell types | 15 |
diabetic patients | 15 |
three groups | 15 |
innate immune | 15 |
extracellular matrix | 15 |
induced senescence | 15 |
respiratory tract | 14 |
receptor ace | 14 |
membrane fusion | 14 |
receptor gene | 14 |
diabetic mice | 14 |
may contribute | 14 |
ii production | 14 |
angiotensin iv | 14 |
human angiotensin | 14 |
lipid accumulation | 14 |
ras activity | 14 |
neurogenic hypertension | 14 |
hospitalized patients | 14 |
nadph oxidase | 14 |
animal model | 14 |
renin inhibitors | 14 |
kinin system | 14 |
nuclear factor | 14 |
proinflammatory cytokines | 14 |
heart function | 14 |
organ damage | 14 |
highly expressed | 14 |
plasma renin | 14 |
expressing cells | 14 |
insulin receptor | 14 |
may lead | 14 |
lipid metabolism | 14 |
mas receptors | 14 |
pressure regulation | 14 |
retrospective cohort | 14 |
ace angiotensin | 14 |
experimental models | 14 |
clinical course | 14 |
ii induces | 14 |
binding protein | 13 |
critical role | 13 |
pulmonary fibrosis | 13 |
ras genes | 13 |
viral infections | 13 |
angiotensin iii | 13 |
related carboxypeptidase | 13 |
cardiac myocytes | 13 |
endothelial cell | 13 |
local tissue | 13 |
significant association | 13 |
muscle cell | 13 |
reticulum stress | 13 |
dm ab | 13 |
case series | 13 |
cancer cells | 13 |
alveolar cells | 13 |
cancer risk | 13 |
central role | 13 |
extracellular signal | 13 |
cell surface | 13 |
enzyme activity | 13 |
adjusted estimates | 13 |
spike glycoprotein | 13 |
renin inhibitor | 13 |
human podocytes | 13 |
podocyte loss | 13 |
tyrosine kinases | 13 |
critical disease | 13 |
masr axis | 13 |
induced diabetic | 13 |
lung fibrosis | 13 |
receptor antagonists | 13 |
animal studies | 12 |
protective arm | 12 |
mitochondrial dysfunction | 12 |
cov infection | 12 |
filtration barrier | 12 |
brain renin | 12 |
viral rna | 12 |
therapeutic targets | 12 |
regulated kinase | 12 |
significantly increased | 12 |
mitochondrial fission | 12 |
statistically significant | 12 |
enzyme gene | 12 |
angiotensin peptides | 12 |
ab group | 12 |
high blood | 12 |
lung disease | 12 |
virus entry | 12 |
coronary artery | 12 |
cell membrane | 12 |
receptor binding | 12 |
pathological conditions | 12 |
viral particles | 12 |
clinical implications | 12 |
lower risk | 12 |
pulmonary vascular | 12 |
receptor tyrosine | 12 |
podocyte damage | 12 |
type diabetic | 12 |
key role | 12 |
induced podocyte | 12 |
subgroup analysis | 12 |
intrarenal ras | 12 |
high dose | 12 |
viral replication | 11 |
type ii | 11 |
gtpase activity | 11 |
pathological changes | 11 |
like receptor | 11 |
foot processes | 11 |
vascular permeability | 11 |
neutral amino | 11 |
direct renin | 11 |
plasma levels | 11 |
converts angiotensin | 11 |
activated ras | 11 |
plasma acetate | 11 |
may play | 11 |
biologically active | 11 |
significant difference | 11 |
human renin | 11 |
recombinant ace | 11 |
ras imbalance | 11 |
lung function | 11 |
mice lacking | 11 |
system blockers | 11 |
glomerular basement | 11 |
east respiratory | 11 |
cardiac fibrosis | 11 |
detrimental effects | 11 |
sars virus | 11 |
multiple comparisons | 11 |
cardiovascular risk | 11 |
ace may | 11 |
enzyme angiotensin | 11 |
arterial hypertension | 11 |
disease progression | 11 |
mortality estimates | 11 |
clinical data | 11 |
actin cytoskeleton | 11 |
negative regulator | 11 |
systemic inflammation | 11 |
glomerular podocytes | 11 |
heart disease | 11 |
receptor subtypes | 11 |
cardiac fibroblasts | 11 |
ras may | 11 |
produce ang | 11 |
exposure time | 11 |
endothelial function | 11 |
active sites | 11 |
nep may | 11 |
high risk | 11 |
previous studies | 11 |
induced cardiac | 11 |
spike proteins | 11 |
soluble ace | 11 |
small intestine | 11 |
renal angiotensin | 10 |
yeast two | 10 |
several studies | 10 |
ras systems | 10 |
structural basis | 10 |
immune complexes | 10 |
transduction pathways | 10 |
type alveolar | 10 |
oxide synthase | 10 |
mesangial cells | 10 |
subfornical organ | 10 |
immune cells | 10 |
side effects | 10 |
brush border | 10 |
diabetic renal | 10 |
gut dysbiosis | 10 |
injury angiotensin | 10 |
therapeutic potential | 10 |
ii formation | 10 |
rats angiotensin | 10 |
control study | 10 |
inflammatory responses | 10 |
mortality rates | 10 |
inflammatory effects | 10 |
cardiac remodeling | 10 |
positive patients | 10 |
foot process | 10 |
acid transporter | 10 |
functional expression | 10 |
signaling mechanisms | 10 |
receptor stimulation | 10 |
expression levels | 10 |
dependent manner | 10 |
associated protein | 10 |
ii infusion | 10 |
assisted surgery | 10 |
clinical features | 10 |
pulmonary disease | 10 |
mast cell | 10 |
diabetic kidney | 10 |
robotic assisted | 10 |
segmental glomerulosclerosis | 10 |
serine threonine | 10 |
pulmonary vasoconstriction | 10 |
physiological functions | 10 |
protein levels | 10 |
one study | 10 |
transforming activity | 10 |
mucociliary clearance | 10 |
may increase | 10 |
electron microscopy | 10 |
transgenic rats | 10 |
significantly higher | 10 |
essential role | 10 |
artery disease | 10 |
middle east | 10 |
receptor subtype | 9 |
long term | 9 |
catalytic activity | 9 |
acid residues | 9 |
cytokine production | 9 |
creative commons | 9 |
induced vsmc | 9 |
decreased expression | 9 |
inflammatory cells | 9 |
renal fibrosis | 9 |
binding sites | 9 |
critically ill | 9 |
taken together | 9 |
patients may | 9 |
ejection fraction | 9 |
previous sars | 9 |
testosterone deficiency | 9 |
glycogen synthase | 9 |
mortality rate | 9 |
glomus cells | 9 |
glucose uptake | 9 |
proximal tubule | 9 |
lower odds | 9 |
clinical trial | 9 |
tyrosine kinase | 9 |
higher crude | 9 |
protein interactions | 9 |
ras dysregulation | 9 |
studies using | 9 |
egf receptor | 9 |
cardiovascular complications | 9 |
human homolog | 9 |
ras overactivation | 9 |
mortality among | 9 |
human lung | 9 |
recent studies | 9 |
pulmonary ras | 9 |
salt hypertension | 9 |
mg ml | 9 |
cell signaling | 9 |
diabetic complications | 9 |
cardiac angiotensin | 9 |
vascular inflammation | 9 |
bound ace | 9 |
renin receptors | 9 |
essential regulator | 9 |
spike receptor | 9 |
ace expressing | 9 |
podocyte hypertrophy | 9 |
local renin | 9 |
receptor type | 9 |
cell biology | 9 |
db mice | 9 |
resistant hypertension | 9 |
recent study | 9 |
induced hypertension | 9 |
lung ventilation | 9 |
lung failure | 9 |
renin prorenin | 9 |
increased plasma | 9 |
induced vascular | 9 |
insulin sensitivity | 9 |
skeletal muscle | 9 |
ii generation | 9 |
cardiac injury | 9 |
system blockade | 9 |
angiotensin peptide | 9 |
human vascular | 9 |
focal segmental | 9 |
null mice | 9 |
pulmonary blood | 9 |
ras inhibition | 9 |
epicardial adipose | 9 |
risk factor | 8 |
original studies | 8 |
lung damage | 8 |
ii stimulates | 8 |
china clinical | 8 |
podocyte detachment | 8 |
previously described | 8 |
glucose transporter | 8 |
cells within | 8 |
also found | 8 |
inflammatory cytokine | 8 |
clinical relevance | 8 |
general population | 8 |
transcription factors | 8 |
cell rna | 8 |
pivotal role | 8 |
systemic ras | 8 |
insertion deletion | 8 |
ace imbalance | 8 |
well established | 8 |
tissue ace | 8 |
secretory phenotype | 8 |
plasminogen activator | 8 |
new therapeutic | 8 |
corona virus | 8 |
mrna levels | 8 |
linked genes | 8 |
new coronavirus | 8 |
human heart | 8 |
glomerular diseases | 8 |
palmitic acid | 8 |
mesenchymal transition | 8 |
akita mice | 8 |
genes involved | 8 |
length human | 8 |
cancer patients | 8 |
hypertensive rat | 8 |
high levels | 8 |
hypoxic pulmonary | 8 |
myocardial fibrosis | 8 |
cell senescence | 8 |
orx group | 8 |
mice angiotensin | 8 |
cell body | 8 |
cells via | 8 |
pooled analysis | 8 |
novel angiotensin | 8 |
increased ang | 8 |
tissue distribution | 8 |
breast cancer | 8 |
serum angiotensin | 8 |
apical membrane | 8 |
metabolic syndrome | 8 |
gene deletion | 8 |
cell apoptosis | 8 |
reduced ace | 8 |
generating ang | 8 |
adult inpatients | 8 |
nep expression | 8 |
db db | 8 |
sympathetic nervous | 8 |
sodium delivery | 8 |
saccharomyces cerevisiae | 8 |
ras plays | 8 |
juxtaglomerular cells | 8 |
pressure elevation | 8 |
circulating ang | 8 |
antibiotic intervention | 8 |
mechanical stress | 8 |
outcomes among | 8 |
binding site | 8 |
mediated virus | 8 |
dependent pathways | 8 |
adrenal gland | 8 |
observational studies | 8 |
ras signaling | 8 |
receptor activation | 8 |
ras derivatives | 8 |
induced acute | 8 |
serum ace | 8 |
coronavirus nl | 8 |
virus replication | 8 |
activity may | 8 |
tumor growth | 8 |
patients taking | 8 |
tissue damage | 8 |
performed using | 8 |
high level | 8 |
antihypertensive drugs | 8 |
aortic aneurysm | 8 |
intrarenal renin | 8 |
beneficial effect | 8 |
podocyte injuries | 8 |
lung epithelial | 8 |
yeast strains | 8 |
natriuretic peptide | 8 |
serine proteases | 8 |
second messenger | 8 |
renal ace | 8 |
bone metabolism | 8 |
serine protease | 8 |
circulating renin | 8 |
increasing ace | 8 |
care units | 8 |
potential role | 8 |
pulmonary arterial | 8 |
cell lung | 8 |
two groups | 8 |
coronavirus pneumonia | 8 |
intracellular ang | 8 |
renal hypertrophy | 7 |
connective tissue | 7 |
significant differences | 7 |
vascular remodeling | 7 |
low dose | 7 |
receptor expression | 7 |
viral spike | 7 |
enzyme protects | 7 |
fatty acid | 7 |
diabetic retinopathy | 7 |
might lead | 7 |
previously reported | 7 |
kinase inhibitor | 7 |
transmembrane serine | 7 |
respiratory diseases | 7 |
density lipoprotein | 7 |
higher expression | 7 |
entry receptor | 7 |
glomerular sclerosis | 7 |
abdominal aortic | 7 |
glomerular podocyte | 7 |
mechanical ventilation | 7 |
type mice | 7 |
genetic ace | 7 |
rat liver | 7 |
receptors mediate | 7 |
linked mental | 7 |
supplementary table | 7 |
inhibitory activity | 7 |
insensitive carboxypeptidase | 7 |
may provide | 7 |
kinase kinase | 7 |
sars patients | 7 |
bone mineral | 7 |
ace balance | 7 |
myocardial ace | 7 |
sars pathogenesis | 7 |
brain angiotensin | 7 |
induce podocyte | 7 |
angiotensin systems | 7 |
membranous nephropathy | 7 |
hospital mortality | 7 |
patients hospitalized | 7 |
mineral density | 7 |
ace activities | 7 |
including hypertension | 7 |
targeted derivatives | 7 |
acid linker | 7 |
adverse effects | 7 |
ace function | 7 |
bone mass | 7 |
i converting | 7 |
diabetic conditions | 7 |
neprilysin inhibition | 7 |
cardiac function | 7 |
increased susceptibility | 7 |
right ventricular | 7 |
orally active | 7 |
sodium retention | 7 |
diabetes infected | 7 |
observational study | 7 |
clinical severity | 7 |
vascular aging | 7 |
signaling events | 7 |
bronchial epithelial | 7 |
cellular receptor | 7 |
ace converts | 7 |
mental retardation | 7 |
underlying mechanisms | 7 |
dysregulated ras | 7 |
receptor agonist | 7 |
beneficial role | 7 |
african americans | 7 |
renin hypertension | 7 |
cellular responses | 7 |
cardiovascular effects | 7 |
positive feedback | 7 |
intracellular renin | 7 |
ulcerative colitis | 7 |
renal cells | 7 |
macrophage infiltration | 7 |
therapeutic role | 7 |
ventrolateral medulla | 7 |
data suggest | 7 |
membrane proteins | 7 |
experimental evidence | 7 |
mouse models | 7 |
biological effects | 7 |
tissue growth | 7 |
study showed | 7 |
dependent mechanism | 7 |
world health | 7 |
authors declare | 7 |
hypertensive nephrosclerosis | 7 |
human subjects | 7 |
also expressed | 7 |
carotid body | 7 |
cov spike | 7 |
another study | 7 |
without affecting | 7 |
golgi membranes | 7 |
cultured human | 7 |
renal tissue | 7 |
reduced risk | 7 |
crude mortality | 7 |
cellular entry | 7 |
hepatic stellate | 7 |
inhibitors angiotensin | 7 |
vitro studies | 7 |
advanced glycation | 7 |
first step | 7 |
may result | 7 |
ii also | 7 |
target cells | 7 |
stem cells | 7 |
slit diaphragm | 7 |
two axes | 7 |
significantly associated | 7 |
gastric cancer | 7 |
hxt gene | 7 |
transmembrane protein | 7 |
crystal structure | 7 |
dawley rats | 7 |
vascular disease | 7 |
mg kg | 7 |
lamina propria | 7 |
increases ace | 7 |
rodent models | 7 |
elderly patients | 7 |
chronic diseases | 7 |
cells angiotensin | 7 |
glycation end | 7 |
terminal transmembrane | 7 |
health organization | 7 |
patients treated | 7 |
active renin | 7 |
structural proteins | 7 |
acute myocardial | 7 |
gene variants | 7 |
inflammatory mediators | 7 |
vascular endothelium | 7 |
ace cleaves | 7 |
significant decrease | 7 |
sex hormones | 7 |
inflammatory diseases | 7 |
growth factors | 7 |
coronavirus sars | 7 |
disease model | 7 |
chemoattractant protein | 7 |
fatality rate | 7 |
viral load | 7 |
receptor angiotensin | 7 |
targeting signal | 7 |
tyrosine phosphorylation | 7 |
inflammatory reactions | 7 |
bradykinin receptor | 7 |
superoxide production | 7 |
opg rankl | 6 |
molecular basis | 6 |
significantly elevated | 6 |
important roles | 6 |
patients admitted | 6 |
terminal dipeptide | 6 |
antihypertensive agents | 6 |
ii effects | 6 |
unfolded protein | 6 |
linker region | 6 |
derived ros | 6 |
epidemiological studies | 6 |
ii signaling | 6 |
receptor recognition | 6 |
homologue ace | 6 |
ace functions | 6 |
erbb family | 6 |
adaptive immune | 6 |
lung inflammation | 6 |
patients requiring | 6 |
terminal domain | 6 |
podocytes cultured | 6 |
mineralocorticoid receptor | 6 |
structural studies | 6 |
mediated stimulation | 6 |
may occur | 6 |
deletion polymorphism | 6 |
cells expressing | 6 |
hour group | 6 |
glycogen phosphorylase | 6 |
ace activation | 6 |
adjusted mortality | 6 |
dependent kinase | 6 |
two active | 6 |
higher risk | 6 |
em structure | 6 |
expression data | 6 |
cell killing | 6 |
kidney injuries | 6 |
ras family | 6 |
peptide ang | 6 |
arbs may | 6 |
ace ectodomain | 6 |
circulating ace | 6 |
monocyte chemoattractant | 6 |
isolated perfused | 6 |
slgt inhibitors | 6 |
significant reduction | 6 |
biochemical indexes | 6 |
including vasoconstriction | 6 |
evidence indicates | 6 |
might also | 6 |
acid linkers | 6 |
chronic hepatitis | 6 |
mas expression | 6 |
viral loads | 6 |
lipoprotein receptor | 6 |
animal experiments | 6 |
renal damage | 6 |
two isoforms | 6 |
autophagosome formation | 6 |
recent meta | 6 |
new york | 6 |
drug resistance | 6 |
hour groups | 6 |
regulatory role | 6 |
understanding sars | 6 |
receptors may | 6 |
chronic liver | 6 |
studies included | 6 |
ros production | 6 |
phase ii | 6 |
infected cells | 6 |
studies showing | 6 |
rostral ventrolateral | 6 |
crude rate | 6 |
chronic inflammatory | 6 |
gene polymorphism | 6 |
ace genes | 6 |
small cell | 6 |
large number | 6 |
epithelial cell | 6 |
converts ang | 6 |
prostate cancer | 6 |
tissue renin | 6 |
atp ap | 6 |
also reported | 6 |
ottawa scale | 6 |
ventricular hypertrophy | 6 |
cov receptor | 6 |
type angiotensin | 6 |
lower blood | 6 |
retrospective case | 6 |
water reabsorption | 6 |
bone loss | 6 |
hypertension angiotensin | 6 |
ischemia reperfusion | 6 |
patients linked | 6 |
reperfusion injury | 6 |
chromosome inactivation | 6 |
process effacement | 6 |
increased mortality | 6 |
intracellular signaling | 6 |
east asian | 6 |
furin cleavage | 6 |
ventricular dysfunction | 6 |
renin inhibition | 6 |
protein response | 6 |
forming enzymes | 6 |
induced apoptosis | 6 |
ii blockade | 6 |
immune complex | 6 |
molecular weight | 6 |
domain complexed | 6 |
protein kinases | 6 |
well documented | 6 |
cell survival | 6 |
diseases associated | 6 |
kinase activation | 6 |
lung cells | 6 |
membrane versions | 6 |
pulmonary neuroendocrine | 6 |
intestinal ace | 6 |
supplementary material | 6 |
wide variety | 6 |
severe pneumonia | 6 |
microvascular thrombosis | 6 |
mrna expressions | 6 |
ill patients | 6 |
potassium wasting | 6 |
cell cycle | 6 |
small molecule | 6 |
liver injury | 6 |
mediates regulated | 6 |
plasma angiotensin | 6 |
inflammatory pathways | 6 |
ii concentration | 6 |
cardiovascular aging | 6 |
water retention | 6 |
releasing peptide | 6 |
will provide | 6 |
terminal lipid | 6 |
evidence supporting | 6 |
human bronchial | 6 |
innate immunity | 6 |
hybrid system | 6 |
controlled trial | 6 |
somatic ace | 6 |
renal diseases | 6 |
immune function | 6 |
lipid raft | 6 |
higher ace | 6 |
kinase activity | 6 |
pulmonary diseases | 6 |
antifibrotic effects | 6 |
acid transporters | 6 |
associated secretory | 6 |
western blot | 6 |
therapeutic approaches | 6 |
muscle weakness | 6 |
ras axis | 6 |
endogenous ligand | 6 |
lipid modifications | 6 |
extracellular vesicles | 6 |
transmembrane anchor | 6 |
water absorption | 6 |
recent years | 6 |
distinct roles | 6 |
platelet aggregation | 6 |
molecular mechanism | 6 |
protein priming | 6 |
case reports | 6 |
dependent endocytosis | 6 |
podocyte depletion | 6 |
reduced expression | 6 |
vascular dysfunction | 6 |
exclusively hypertensive | 6 |
upregulate ace | 6 |
fold higher | 6 |
disease states | 6 |
brain nuclei | 6 |
i receptor | 6 |
transcription factor | 6 |
human tissues | 6 |
systemic circulation | 6 |
lumbar vertebra | 6 |
may cause | 6 |
active peptide | 6 |
two different | 6 |
high ace | 6 |
may serve | 6 |
higher mortality | 6 |
new insights | 6 |
ncov infected | 6 |
independent mechanisms | 6 |
acute coronary | 6 |
angiotensinogen gene | 6 |
case fatality | 6 |
early stage | 6 |
randomised trial | 6 |
signal pathway | 6 |
molecular biology | 6 |
pressure response | 6 |
damage caused | 6 |
main effector | 6 |
promoting effects | 6 |
regulated ectodomain | 6 |
original sars | 6 |
circulating levels | 6 |
ras might | 6 |
lung adenocarcinoma | 6 |
regulated aminopeptidase | 6 |
endocytic pathway | 6 |
tissue levels | 6 |
adrenergic receptor | 6 |
glomerular injury | 6 |
induced obesity | 6 |
poor outcomes | 5 |
inhibitors may | 5 |
significantly decreased | 5 |
ii angiotensin | 5 |
arterial pressure | 5 |
closely related | 5 |
increased tissue | 5 |
vlp group | 5 |
regulate blood | 5 |
global pandemic | 5 |
drug classes | 5 |
ras drugs | 5 |
ras within | 5 |
linker regions | 5 |
two distinct | 5 |
inflammatory bowel | 5 |
current study | 5 |
potential target | 5 |
circulating angiogenic | 5 |
mesangial matrix | 5 |
ras fusion | 5 |
predominantly expressed | 5 |
neuroendocrine cells | 5 |
pathway analysis | 5 |
therapeutic strategy | 5 |
aii levels | 5 |
rats treated | 5 |
expression profiling | 5 |
potential risk | 5 |
aortic senescence | 5 |
whereas ace | 5 |
working modes | 5 |
therapeutic strategies | 5 |
cell damage | 5 |
inflammatory conditions | 5 |
novel target | 5 |
ace inhibitory | 5 |
glomerular endothelial | 5 |
mediated effects | 5 |
related diseases | 5 |
tubular injury | 5 |
chaperone proteins | 5 |
commons attribution | 5 |
coding sequence | 5 |
may require | 5 |
biological actions | 5 |
inhibitory peptides | 5 |
antithrombotic effect | 5 |
mg day | 5 |
ras also | 5 |
adenine dinucleotide | 5 |
increased covid | 5 |
peptide metabolism | 5 |
blood glucose | 5 |
body weight | 5 |
brain regions | 5 |
aged mice | 5 |
fat diet | 5 |
therapeutic implications | 5 |
heparan sulfate | 5 |
present study | 5 |
severe course | 5 |
ace null | 5 |
systolic blood | 5 |
acetate levels | 5 |
controlled trials | 5 |
aldosterone secretion | 5 |
plant food | 5 |
five studies | 5 |
angiotensinogen mrna | 5 |
ii may | 5 |
soluble form | 5 |
quality assessment | 5 |
digestive system | 5 |
many patients | 5 |
survival benefit | 5 |
small studies | 5 |
clinical practice | 5 |
carboxypeptidase ace | 5 |
systemic ang | 5 |
higher plasma | 5 |
interaction inhibitors | 5 |
enzymatic activity | 5 |
metabolism disorder | 5 |
ace replacement | 5 |
analysis based | 5 |
mediated senescence | 5 |
ii pneumocytes | 5 |
target organ | 5 |
organ dysfunction | 5 |
chronic inflammation | 5 |
facilitates viral | 5 |
biological functions | 5 |
inflammatory lung | 5 |
end products | 5 |
systolic dysfunction | 5 |
factor beta | 5 |
emerging evidence | 5 |
ras function | 5 |
important factor | 5 |
associated coronavirus | 5 |
arterial stiffness | 5 |
new class | 5 |
subsequent studies | 5 |
sexual dimorphism | 5 |
fda approved | 5 |
growth arrest | 5 |
higher rates | 5 |
may reduce | 5 |
ventricular remodeling | 5 |
vlp groups | 5 |
differential expression | 5 |
cellular growth | 5 |
ko mice | 5 |
expression may | 5 |
sd proteins | 5 |
renal sodium | 5 |
negatively regulates | 5 |
inflammatory drugs | 5 |
studies showed | 5 |
immunofluorescence staining | 5 |
renin release | 5 |
substrate specificity | 5 |
cirrhotic patients | 5 |
captopril treatment | 5 |
senescence appears | 5 |
vascular system | 5 |
pressure overload | 5 |
confirmed covid | 5 |
mesenchymal cells | 5 |
human angiotensinconverting | 5 |
studies reported | 5 |
smad signal | 5 |
chymase inhibitors | 5 |
risk group | 5 |
receptor pathway | 5 |
diseases including | 5 |
myocardial ischemia | 5 |
patients receiving | 5 |
rate among | 5 |
arb use | 5 |
ventilated patients | 5 |
may account | 5 |
rna virus | 5 |
focus forming | 5 |
retrospective study | 5 |
angiogenic cells | 5 |
cancer cell | 5 |
factors associated | 5 |
skeletal ras | 5 |
hypertensive mice | 5 |
whether ras | 5 |
literature review | 5 |
protease inhibitor | 5 |
kinase inhibitors | 5 |
plasma ang | 5 |
podocyte foot | 5 |
particular interest | 5 |
bone area | 5 |
probe sets | 5 |
tissue factor | 5 |
lung compliance | 5 |
pathological cardiac | 5 |
angii infusion | 5 |
urinary protein | 5 |
urinary potassium | 5 |
respiratory disease | 5 |
glomerular hypertrophy | 5 |
brain barrier | 5 |
host receptor | 5 |
primers vk | 5 |
clinical evidence | 5 |
nonproteolytic activation | 5 |
elevated blood | 5 |
local production | 5 |
disease angiotensin | 5 |
mice exhibit | 5 |
chronic administration | 5 |
infected pneumonia | 5 |
pancreatic cancer | 5 |
high concentration | 5 |
akt pathway | 5 |
study indicated | 5 |
atrial fibrillation | 5 |
insulin secretion | 5 |
mice expressing | 5 |
differential effects | 5 |
rat intestine | 5 |
direct effect | 5 |
recently demonstrated | 5 |
hospitalised patients | 5 |
myocardial dysfunction | 5 |
possible mechanisms | 5 |
cardiovascular implications | 5 |
ras gene | 5 |
nucleus tractus | 5 |
two patients | 5 |
dna damage | 5 |
human disease | 5 |
results suggest | 5 |
lupus nephritis | 5 |
whereas ang | 5 |
term sequelae | 5 |
dd genotype | 5 |
life span | 5 |
even though | 5 |
ras involvement | 5 |
among covid | 5 |
downregulate ace | 5 |
new target | 5 |
analysis reported | 5 |
oral mucosa | 5 |
blockade inhibits | 5 |
ace knockout | 5 |
also shown | 5 |
cause transformation | 5 |
randomised controlled | 5 |
alpha convertase | 5 |
preserved ejection | 5 |
induced colitis | 5 |
literature search | 5 |
forming enzyme | 5 |
also inhibit | 5 |
drug development | 5 |
kinase pathway | 5 |
hypertension hospitalized | 5 |
low levels | 5 |
catalytically active | 5 |
public health | 5 |
immune genes | 5 |
gut microbiome | 5 |
fibrotic effects | 5 |
primary target | 5 |
less likely | 5 |
yeast cells | 5 |
although ace | 5 |
chronic heart | 5 |
physiological conditions | 5 |
human studies | 5 |
peroxisome proliferator | 5 |
upper respiratory | 5 |
fatal outcomes | 5 |
recently reported | 5 |
nicotinamide adenine | 5 |
activator inhibitor | 5 |
secondary antibody | 5 |
extracellular domain | 5 |
filtration membrane | 5 |
study association | 5 |
different populations | 5 |
adhesion molecules | 5 |
neurotransmitter release | 5 |
adhesion molecule | 5 |
senescent cell | 5 |
encodes aminopeptidase | 5 |
protein synthesis | 5 |
monoclonal antibody | 5 |
septic shock | 5 |
therapeutic effects | 5 |
current pandemic | 5 |
serum ang | 5 |
rat hearts | 5 |
stellate cells | 5 |
renal dysfunction | 5 |
glomerular hypertension | 5 |
early phase | 5 |
estrogen receptor | 5 |
study reported | 5 |
putative receptor | 5 |
tissue inflammation | 5 |
cardiac involvement | 5 |
model predicts | 5 |
gene transfer | 5 |
ace i | 5 |
underlying mechanism | 5 |
drugs targeting | 5 |
pathological hypertrophy | 5 |
fanconi syndrome | 5 |
portal hypertensive | 5 |
increase ace | 5 |
blood volume | 5 |
transmembrane protease | 5 |
widely used | 5 |
bone resorption | 5 |
ii level | 5 |
endothelial nitric | 5 |
experimental studies | 5 |
paraventricular nucleus | 5 |
urine potassium | 5 |
bile duct | 5 |
also called | 5 |
cardiac failure | 5 |
vascular injury | 5 |
recombinant angiotensin | 5 |
membrane bound | 5 |
generate ang | 5 |
also causes | 5 |
dinucleotide phosphate | 5 |
therapeutic intervention | 5 |
ace overexpression | 5 |
open access | 5 |
evidence supports | 5 |
national health | 5 |
ace pathways | 5 |
also showed | 5 |
times higher | 4 |
expiratory pressure | 4 |
ace structure | 4 |
novel angiotensinconverting | 4 |
indirectly via | 4 |
system may | 4 |
study design | 4 |
prone posturing | 4 |
minimal change | 4 |
dj donoghue | 4 |
see note | 4 |
compensatory mechanisms | 4 |
tractus solitarius | 4 |
gene transcripts | 4 |
cardiac disease | 4 |
proven protease | 4 |
inhibits development | 4 |
dm rats | 4 |
signaling via | 4 |
recent evidence | 4 |
convoluted tubule | 4 |
local pulmonary | 4 |
periodic acid | 4 |
arbs reduce | 4 |
hematopoietic stem | 4 |
hubei province | 4 |
cd ap | 4 |
study demonstrated | 4 |
diminazene aceturate | 4 |
coronary syndrome | 4 |
competing interests | 4 |
genetic analysis | 4 |
hour vs | 4 |
therapeutic agents | 4 |
inhibitor therapy | 4 |
endothelial ace | 4 |
clinical presentation | 4 |
cd cells | 4 |
respiratory system | 4 |
aortic stiffness | 4 |
specific antibody | 4 |
antihypertensive effect | 4 |
reduced myocardial | 4 |
ras anchored | 4 |
rat angiotensin | 4 |
polymerase chain | 4 |
mediated cytotoxicity | 4 |
nucleotide polymorphisms | 4 |
within several | 4 |
disease susceptibility | 4 |
central ang | 4 |
domain receptor | 4 |
renal impairment | 4 |
vascular resistance | 4 |
growing evidence | 4 |
differentially expressed | 4 |
many organs | 4 |
biased expression | 4 |
infection may | 4 |
sympathetic neurons | 4 |
prospective cohort | 4 |
related disease | 4 |
reported mortality | 4 |
cancer therapeutics | 4 |
chain reaction | 4 |
antihypertensive therapy | 4 |
hemodynamic effects | 4 |
sequence identity | 4 |
transmission electron | 4 |
tissue homeostasis | 4 |
evidence suggesting | 4 |
enzyme type | 4 |
co insufflation | 4 |
form angiotensin | 4 |
cardiovascular dysfunction | 4 |
receptor promotes | 4 |
human angiotensinogen | 4 |
receptor via | 4 |
severity outcomes | 4 |
situ hybridization | 4 |
endopeptidase activity | 4 |
asian populations | 4 |
vascular complications | 4 |
actions via | 4 |
matrix expansion | 4 |
precursor protein | 4 |
proinflammatory cytokine | 4 |
cellular signaling | 4 |
intracerebroventricular infusion | 4 |
system renin | 4 |
axis ace | 4 |
risk individuals | 4 |
protein interaction | 4 |
protease serine | 4 |
angii antagonists | 4 |
may act | 4 |
deleterious actions | 4 |
renin secretion | 4 |
mice models | 4 |
potential influence | 4 |
blocking drugs | 4 |
rat intestinal | 4 |
proteolytic activation | 4 |
also involved | 4 |
acid transport | 4 |
negatively charged | 4 |
biliary fibrosis | 4 |
golgi compartment | 4 |
also responsible | 4 |
transmembrane glycoprotein | 4 |
increased intracellular | 4 |
ace downregulation | 4 |
distal sodium | 4 |
premature aging | 4 |
like particles | 4 |
terminal amino | 4 |
either ace | 4 |
kidney diseases | 4 |
normal tissue | 4 |
soluble angiotensin | 4 |
lower respiratory | 4 |
cardiovascular patients | 4 |
blood cancer | 4 |
glomerular slit | 4 |
cov family | 4 |
dna fragment | 4 |
activated receptor | 4 |
cov also | 4 |
treatment may | 4 |
adam activity | 4 |
cov entry | 4 |
feedback activation | 4 |
regulatory mechanism | 4 |
bladder cancer | 4 |
ras medications | 4 |
induced inflammation | 4 |
entry depends | 4 |
odds ratio | 4 |
lower crude | 4 |
charge barrier | 4 |
ace activators | 4 |
human airway | 4 |
mediated endocytosis | 4 |
ten studies | 4 |
regulated glycogen | 4 |
ii produced | 4 |
vascular damage | 4 |
lung adenocarcinomas | 4 |
increased oxidative | 4 |
diabetic cardiovascular | 4 |
conjugated goat | 4 |
golgi targeting | 4 |
american hypertensives | 4 |
genetic variants | 4 |
therapeutic effect | 4 |
bowel disease | 4 |
ace ko | 4 |
potential therapy | 4 |
bat origin | 4 |
protein coupled | 4 |
cyclic ang | 4 |
catalytic domain | 4 |
may represent | 4 |
glomerular endothelium | 4 |
interstitial oedema | 4 |
vascular wall | 4 |
may explain | 4 |
several mechanisms | 4 |
may influence | 4 |
antagonist candesartan | 4 |
data analysis | 4 |
light microscopy | 4 |
hepatic fibrogenesis | 4 |
coronavirus entry | 4 |
potent anti | 4 |
including il | 4 |
ras upregulation | 4 |
arterial wall | 4 |
drug discovery | 4 |
binding proteins | 4 |
ii activation | 4 |
lower levels | 4 |
tissue ang | 4 |
apelin receptor | 4 |
terminal kinase | 4 |
enhanced thrombosis | 4 |
aberrant ras | 4 |
antisense inhibition | 4 |
ventricular fibrillation | 4 |
superoxide dismutase | 4 |
closely resembles | 4 |
increased angiotensin | 4 |
hypokalaemia compared | 4 |
mesangial expansion | 4 |
studies also | 4 |
surface ace | 4 |
microbiota might | 4 |
pathways angiotensin | 4 |
factor alpha | 4 |
natriuretic peptides | 4 |
double membrane | 4 |
also stimulates | 4 |
cada cassette | 4 |
higher affinity | 4 |
including heart | 4 |
group compared | 4 |
tmprss cleavage | 4 |
cerebral artery | 4 |
dependent senescence | 4 |
targeting function | 4 |
carboxypeptidase angiotensin | 4 |
individual genetic | 4 |
increased blood | 4 |
cirrhotic liver | 4 |
renal renin | 4 |
widely expressed | 4 |
kill tumor | 4 |
full text | 4 |
arterial aging | 4 |
gene reprogramming | 4 |
binding affinity | 4 |
threonine kinases | 4 |
cell lines | 4 |
reduced compared | 4 |
cytoplasmic tail | 4 |
cytokine profile | 4 |
careful targeting | 4 |
mediated activation | 4 |
components required | 4 |
short half | 4 |
lung fibroblasts | 4 |
clinically proven | 4 |
programmed cell | 4 |
silent hypoxia | 4 |
cohort studies | 4 |
antihypertensive effects | 4 |
opposing effects | 4 |
vsmc phenotype | 4 |
mediated via | 4 |
mechanism underlying | 4 |
ards therapy | 4 |
severe cases | 4 |
comparative study | 4 |
pulmonary ace | 4 |
subgroup analyses | 4 |
still unclear | 4 |
probable bat | 4 |
autophagic flux | 4 |
derived growth | 4 |
complex mechanisms | 4 |
handle region | 4 |
viral pneumonia | 4 |
protective arms | 4 |
bamhi site | 4 |
respiratory infections | 4 |
catalytic activities | 4 |
enzyme suppresses | 4 |
deficiency disorder | 4 |
evidence suggests | 4 |
also promotes | 4 |
two receptors | 4 |
renal failure | 4 |
large body | 4 |
lung diseases | 4 |
pathological features | 4 |
healthy adults | 4 |
human glomerular | 4 |
induced osteoporosis | 4 |
novel drugs | 4 |
protease tmprss | 4 |
heat shock | 4 |
varying degrees | 4 |
airway epithelial | 4 |
internal standard | 4 |
study examining | 4 |
current evidence | 4 |
enzyme inhibitory | 4 |
cq hcq | 4 |
multiple organ | 4 |
positive end | 4 |
randomized controlled | 4 |
mortality compared | 4 |
remains unknown | 4 |
cardiac arrest | 4 |
reduced ratio | 4 |
experimental heart | 4 |
phosphatidyl inositol | 4 |
compensatory increase | 4 |
tract infections | 4 |
ace might | 4 |
protein complex | 4 |
glomerular mesangial | 4 |
biological peptides | 4 |
perfused rat | 4 |
probiotic species | 4 |
nucleotide exchange | 4 |
wuhan clinical | 4 |
forms ang | 4 |
cardiac death | 4 |
shear stress | 4 |
broad spectrum | 4 |
electrolyte disturbances | 4 |
colorectal cancer | 4 |
significantly lower | 4 |
ventilatory support | 4 |
muscle contraction | 4 |
atrial natriuretic | 4 |
nobel prize | 4 |
pressor response | 4 |
intracellular ras | 4 |
reversible association | 4 |
vascular cell | 4 |
higher odds | 4 |
angii type | 4 |
caax motif | 4 |
podocyte sd | 4 |
nasal epithelium | 4 |
myocardial remodeling | 4 |
studies investigating | 4 |
conformational change | 4 |
patients showed | 4 |
oxidase activity | 4 |
poorly oxygenated | 4 |
troponin i | 4 |
distal nephron | 4 |
cerebrospinal fluid | 4 |
increase blood | 4 |
also observed | 4 |
also express | 4 |
reduce lung | 4 |
ras axes | 4 |
signalling pathways | 4 |
protein kc | 4 |
experimental animals | 4 |
collagen deposition | 4 |
last years | 4 |
activation via | 4 |
accentuates vascular | 4 |
liver phosphorylase | 4 |
threatening condition | 4 |
serum levels | 4 |
electrolyte balance | 4 |
cardiothoracic ras | 4 |
human aging | 4 |
neonatal rat | 4 |
partial pressure | 4 |
pneumonia outbreak | 4 |
int cassette | 4 |
lysis buer | 4 |
limiting step | 4 |
like ace | 4 |
matrix metalloproteinase | 4 |
pdr gene | 4 |
coronavirus family | 4 |
approved drugs | 4 |
data suggested | 4 |
like enzymes | 4 |
previous study | 4 |
muscularis mucosa | 4 |
spectrum antibiotics | 4 |
mouse podocytes | 4 |
change disease | 4 |
will lead | 4 |
nk cells | 4 |
sudden cardiac | 4 |
presympathetic neurons | 4 |
regulatory proteins | 4 |
single nucleotide | 4 |
cultured podocytes | 4 |
murine autoimmune | 4 |
ras elements | 4 |
syndrome leads | 4 |
myocardial injury | 4 |
key mechanism | 4 |
protein complexes | 4 |
arterial blood | 4 |
glucose homeostasis | 4 |
till now | 4 |
tissue level | 4 |
family receptors | 4 |
hydrolyze ang | 4 |
ace deletion | 4 |
dependent pathway | 4 |
vascular cells | 4 |
years ago | 4 |
term use | 4 |
site cleft | 4 |
key modulator | 4 |
prefusion conformation | 4 |
clinical use | 4 |
via mas | 4 |
enalapril attenuates | 4 |
intracellular signalling | 4 |
medical literature | 4 |
decoy peptide | 4 |
sham group | 4 |
liquid chromatography | 4 |
data support | 4 |
pressure control | 4 |
ura gene | 4 |
healthy aging | 4 |
loop diuretics | 4 |
mobility group | 4 |
plasma concentration | 4 |
genetic deletion | 4 |
regulated kinases | 4 |
mitigate covid | 4 |
rat lung | 4 |
clinical prognosis | 4 |
cell chymase | 4 |
amyloid beta | 4 |
york city | 4 |
premature senescence | 4 |
rat jejunum | 4 |
statistically non | 4 |
care unit | 4 |
vitro ace | 4 |
fibrosis induced | 4 |
platelet activation | 4 |
rats effect | 4 |
fibroblast growth | 4 |
tract infection | 4 |
vasopressin release | 4 |
rat hepatic | 4 |
tubular lumen | 4 |
receptor function | 4 |
sympathetic nerve | 4 |
treated groups | 4 |
dna synthesis | 4 |
ii acting | 4 |
cardiovascular functions | 4 |
dna sequences | 4 |
increased production | 4 |
deficiency accentuates | 4 |
vivo studies | 4 |
group box | 4 |
risk patients | 4 |
outbreak associated | 4 |
studies suggest | 4 |
minimum distance | 4 |
angiotensinergic signaling | 4 |
via ace | 4 |
diabetic angiotensin | 4 |
related proteins | 4 |
possible role | 4 |
single amino | 4 |
related protein | 4 |
mammalian cells | 4 |
brain tissue | 4 |
lung axis | 4 |
specific receptors | 4 |
threonine kinase | 4 |
kc hart | 4 |
mediated ace | 4 |
hospitalized covid | 4 |
carotid arteries | 4 |
mcd patients | 4 |
examine whether | 4 |
mitochondrial ros | 4 |
descriptive study | 4 |
rna sequencing | 4 |
sympathetic activity | 4 |
cardiovascular events | 4 |
pathway genes | 4 |
iconverting enzyme | 4 |
genes encoding | 4 |
injury response | 4 |
causal relationship | 4 |
respiratory symptoms | 4 |
glycemic control | 4 |
microvascular complications | 4 |
harmful effects | 4 |
histopathological evidence | 4 |
another important | 4 |
cultured rat | 4 |
rat podocytes | 4 |
increasing evidence | 4 |
mapk pathway | 4 |
global loss | 4 |
ras protein | 4 |
intestinal inflammation | 4 |
pdr locus | 4 |
treated rats | 4 |
associated nephropathy | 4 |
chronic ras | 4 |
high mortality | 4 |
time pcr | 4 |
losartan treatment | 4 |
including cell | 4 |
data indicate | 4 |
aortic smooth | 4 |
oriented perspective | 4 |
combinatorial library | 4 |
deficiency leads | 4 |
cardiovascular function | 4 |
highly correlated | 4 |
cells may | 4 |
sd rats | 4 |
soluble flt | 4 |
epidemiological data | 4 |
stem cell | 4 |
strong association | 4 |
two forms | 4 |
dependent ace | 4 |
immunodeficiency virus | 4 |
death rate | 4 |
via angiotensin | 4 |
angiotensin iimediated | 4 |
cov virus | 4 |
small gtpase | 4 |
reduced podocyte | 4 |
renal fanconi | 4 |
cholesterol accumulation | 4 |
protein level | 4 |
disease patients | 4 |
chloride ion | 4 |
ace plays | 4 |
induced endothelial | 4 |
neutrophil chemotaxis | 4 |
treat resistant | 4 |
elevated plasma | 4 |
autonomic dysfunction | 4 |
per se | 4 |
two studies | 4 |
significant role | 4 |
podocyte density | 4 |
genetic polymorphisms | 4 |
inner surface | 4 |
renal tissues | 4 |
high expression | 4 |
receptor mrna | 4 |
gene delivery | 4 |
biological function | 4 |
new components | 4 |
renal potassium | 4 |
cardiovascular hypertrophy | 4 |
functional analysis | 4 |
many years | 4 |
neurons within | 4 |
human cells | 4 |
disease compared | 4 |
point mutation | 4 |
pulmonary edema | 4 |
disease conditions | 4 |
proinflammatory signaling | 4 |
leukocyte adhesion | 4 |
glucose tolerance | 4 |
cellular mechanisms | 4 |
new drugs | 4 |
minimally invasive | 4 |
mitochondrial sirt | 4 |
coupled receptors | 4 |
review article | 4 |
normal physiological | 4 |
factors may | 4 |
apoe knockout | 4 |
usa proc | 4 |
several gene | 4 |
ii antagonist | 4 |
recent reports | 4 |
cre recombinase | 4 |
hong kong | 4 |
related genes | 4 |
low level | 4 |
blood group | 4 |
inflammatory markers | 4 |
mm hg | 4 |
intercellular adhesion | 4 |
system revisited | 3 |
metabolic diseases | 3 |
drugs acting | 3 |
dysfunctional diabetic | 3 |
pulmonary insult | 3 |
two strains | 3 |
histopathological data | 3 |
human gastric | 3 |
cov infections | 3 |
thoracic aortic | 3 |
valproic acid | 3 |
significant changes | 3 |
regulate ace | 3 |
ic values | 3 |
early studies | 3 |
asian countries | 3 |
yeast pdr | 3 |
kidney cortex | 3 |
perivascular fibrosis | 3 |
play important | 3 |
treatment protocols | 3 |
kidney biopsy | 3 |
factor erythroid | 3 |
deeper understanding | 3 |
bronchitis virus | 3 |
reduces hypertension | 3 |
inflammatory thrombocytosis | 3 |
metabolic actions | 3 |
selective inhibitors | 3 |
transcriptional activity | 3 |
endogenous counter | 3 |
vasoactive peptide | 3 |
related factor | 3 |
promotes antithrombotic | 3 |
epithelial brush | 3 |
including angiotensin | 3 |
inflammatory state | 3 |
electronic supplementary | 3 |
recombinant soluble | 3 |
might act | 3 |
renin isoform | 3 |
peer review | 3 |
diabetes rats | 3 |
related coronavirus | 3 |
several factors | 3 |
grade inflammation | 3 |
genetic predispositions | 3 |
induced aaa | 3 |
vascular tone | 3 |
senescence induced | 3 |
cardiovascular pathology | 3 |
inhibiting renin | 3 |
src family | 3 |
antimicrobial peptides | 3 |
vessel exposure | 3 |
newly developed | 3 |
dependent angiotensin | 3 |
ras differentially | 3 |
clinically relevant | 3 |
soluble neprilysin | 3 |
myenteric plexus | 3 |
presenting cells | 3 |
disease progresses | 3 |
colitis model | 3 |
inhibitor use | 3 |
clinical specimens | 3 |
intracellular signal | 3 |
saudi arabia | 3 |
inflammatory sites | 3 |
kinase cascade | 3 |
network analysis | 3 |
senescence markers | 3 |
inhibitors present | 3 |
ras levels | 3 |
proximal metaphysis | 3 |
transtubular potassium | 3 |
treating covid | 3 |
identified throughout | 3 |
enzyme overexpression | 3 |
experimental biliary | 3 |
ace polymorphisms | 3 |
mediated cellular | 3 |
like growth | 3 |
ursodeoxycholic acid | 3 |
tumour necrosis | 3 |
system angiotensin | 3 |
impact gut | 3 |
alpha subunits | 3 |
th anniversary | 3 |
newly identified | 3 |
reporter genes | 3 |
correlation analysis | 3 |
ras status | 3 |
online version | 3 |
excessive scfas | 3 |
oncogenic ras | 3 |
longitudinal muscle | 3 |
dna fragments | 3 |
podocytes may | 3 |
primary antibodies | 3 |
protein aggregation | 3 |
heart chymase | 3 |
room temperature | 3 |
international union | 3 |
long structural | 3 |
induced reactive | 3 |
fulminant hypertension | 3 |
transduction mechanisms | 3 |
might play | 3 |
cell function | 3 |
profound loss | 3 |
eligibility criteria | 3 |
obvious feedback | 3 |
starting point | 3 |
infarct size | 3 |
matrix proteins | 3 |
celecoxib derivative | 3 |
ii caused | 3 |
chinese national | 3 |
additional small | 3 |
utilizes ace | 3 |
arb treatment | 3 |
urinary podocyte | 3 |
critical outcome | 3 |
membrane lipid | 3 |
intervention protocols | 3 |
two major | 3 |
also present | 3 |
positively charged | 3 |
beta integrin | 3 |
renal cortex | 3 |
may constitute | 3 |
well described | 3 |
three key | 3 |
mediated damage | 3 |
tissue samples | 3 |
future therapeutic | 3 |
cause hypokalaemia | 3 |
control animals | 3 |
high affinity | 3 |
factor xiii | 3 |
host membranes | 3 |
binding properties | 3 |
thrombosis may | 3 |
among african | 3 |
cascade activation | 3 |
microvascular endothelium | 3 |
cyclic amp | 3 |
better prognosis | 3 |
extrarenal tissues | 3 |
family members | 3 |
metabolic effects | 3 |
since ras | 3 |
muscularis propria | 3 |
pulmonary tissues | 3 |
ii transmembrane | 3 |
pharmacological inhibition | 3 |
might contribute | 3 |
signaling cascades | 3 |
hyperpermeable yeast | 3 |
protein receptor | 3 |
protein bound | 3 |
human immunodeficiency | 3 |
conflicting findings | 3 |
whilst death | 3 |
altered sasp | 3 |
mesenteric microvascular | 3 |
three main | 3 |
pathways involving | 3 |
edged sword | 3 |
classical renin | 3 |
higher incidence | 3 |
recent discoveries | 3 |
cell responses | 3 |
differences may | 3 |
mediated vasoconstriction | 3 |
potential mechanism | 3 |
pulmonary pathology | 3 |
adenocarcinoma tissue | 3 |
golgi compartments | 3 |
mek erk | 3 |
type receptors | 3 |
gene fragment | 3 |
intestinal epithelial | 3 |
cleavage sites | 3 |
attenuates downregulation | 3 |
sulphonic acid | 3 |
target organs | 3 |
mechanisms underlying | 3 |
ras receptors | 3 |
increased ros | 3 |
retrospective clinical | 3 |
extracellular regulated | 3 |
specific intercellular | 3 |
gastric inflammation | 3 |
gel electrophoresis | 3 |
form ang | 3 |
cirrhotic livers | 3 |
ras must | 3 |
apoptosis pathway | 3 |
receptor genes | 3 |
carcinoma cells | 3 |
time course | 3 |
ii binding | 3 |
mouse brain | 3 |
primarily mediated | 3 |
reverse transcriptase | 3 |
protein binding | 3 |
potassium concentration | 3 |
vaccinated animals | 3 |
protein concentration | 3 |
urine protein | 3 |
volume depletion | 3 |
diastolic dysfunction | 3 |
competitively bind | 3 |
podocyte death | 3 |
respiratory virus | 3 |
specific protein | 3 |
renal physiology | 3 |
highly differentiated | 3 |
one hand | 3 |
physiological relevance | 3 |
key factor | 3 |
reduced inflammation | 3 |
potential application | 3 |
promising therapeutic | 3 |
targeting ras | 3 |
chain fatty | 3 |
presenting characteristics | 3 |
disease due | 3 |
hyaluronic acid | 3 |
downregulating ace | 3 |
severe coronavirus | 3 |
olmesartan treatment | 3 |
associated inflammatory | 3 |
dependent activation | 3 |
eight amino | 3 |
reducing oxidative | 3 |
amino peptidase | 3 |
renal tubules | 3 |
human organs | 3 |
fast green | 3 |
hypertensive covid | 3 |
pancreatic renin | 3 |
mm cl | 3 |
express ace | 3 |
prorenin levels | 3 |
also activate | 3 |
chronic pulmonary | 3 |
glucose transport | 3 |
postmenopausal women | 3 |
randomised trials | 3 |
related mechanisms | 3 |
apoptosis via | 3 |
expression increased | 3 |
induced activation | 3 |
vasoprotective axis | 3 |
risk conditions | 3 |
sex dimorphism | 3 |
cells express | 3 |
bone health | 3 |
cause increased | 3 |
associated inflammation | 3 |
prolyl carboxypeptidase | 3 |
two decades | 3 |
yeast hxt | 3 |
rac rho | 3 |
mainly characterized | 3 |
pathways related | 3 |
marrow dysfunction | 3 |
adverse remodelling | 3 |
surgical smoke | 3 |
intracellular angiotensin | 3 |
virus internalization | 3 |
podocytes via | 3 |
biochemical pathways | 3 |
human small | 3 |
decreased glomerular | 3 |
expresses renin | 3 |
insulin signaling | 3 |
increased activity | 3 |
oxide bioavailability | 3 |
phase i | 3 |
nep activity | 3 |
pulmonary outcome | 3 |
increases vascular | 3 |
human gut | 3 |
nm diameter | 3 |
extracellular region | 3 |
mediated signaling | 3 |
striking differences | 3 |
environmental factors | 3 |
funnel plot | 3 |
ace activator | 3 |
modified yeast | 3 |
expression level | 3 |
vascular repair | 3 |
alzheimer disease | 3 |
new roles | 3 |
play upstream | 3 |
hippocampal ltp | 3 |
cholesterol homeostasis | 3 |
activated via | 3 |
viral ace | 3 |
driving force | 3 |
negative feedback | 3 |
phase reaction | 3 |
key autophagy | 3 |
circulating volume | 3 |
ace also | 3 |
hepatic resistance | 3 |
mice infused | 3 |
comparative map | 3 |
cytoskeletal reorganization | 3 |
gal promoter | 3 |
proinflammatory arm | 3 |
intense research | 3 |
worse covid | 3 |
ischemic stroke | 3 |
virus cell | 3 |
basal cell | 3 |
injury sars | 3 |
available evidence | 3 |
systemic vasculature | 3 |
immune disorder | 3 |
transgenic model | 3 |
nasal epithelial | 3 |
ii synthesis | 3 |
pulmonary damage | 3 |
metabolizing ang | 3 |
sprague dawley | 3 |
free fatty | 3 |
blood urea | 3 |
activation leads | 3 |
human liver | 3 |
lung pathology | 3 |
stress signaling | 3 |
transmissive receptor | 3 |
hydrogen bonds | 3 |
ii clinical | 3 |
rat prorenin | 3 |
myocardial function | 3 |
recent advances | 3 |
elevated ang | 3 |
also reduced | 3 |
medical community | 3 |
like receptors | 3 |
enteric involvement | 3 |
activation promotes | 3 |
gene maps | 3 |
viral myocarditis | 3 |
human ras | 3 |
epithelial side | 3 |
human mesangial | 3 |
increase susceptibility | 3 |
local ang | 3 |
biased agonists | 3 |
activation may | 3 |
bone formation | 3 |
experimental results | 3 |
entering host | 3 |
first place | 3 |
tissue angiotensin | 3 |
cardiovascular homeostasis | 3 |
outlet spigot | 3 |
cell receptor | 3 |
rate limiting | 3 |
glomus cell | 3 |
healthy volunteers | 3 |
related renal | 3 |
receptor usage | 3 |
regulate cardiovascular | 3 |
calcium ions | 3 |
human gastrointestinal | 3 |
stress activities | 3 |
coronavirus receptor | 3 |
vascular diseases | 3 |
ii regulates | 3 |
ras modulator | 3 |
notch signaling | 3 |
gastrointestinal diseases | 3 |
ser thr | 3 |
association study | 3 |
typical acute | 3 |
systematically reviewed | 3 |
santa cruz | 3 |
raf proteins | 3 |
whose expression | 3 |
highly selective | 3 |
also increases | 3 |
reparative function | 3 |
cultured neonatal | 3 |
induced nephropathy | 3 |
mapk signaling | 3 |
erk signaling | 3 |
han chinese | 3 |
circulatory volume | 3 |
thrombus formation | 3 |
may promote | 3 |
functional gut | 3 |
stiffness syndrome | 3 |
healthcare systems | 3 |
experimental model | 3 |
renal proximal | 3 |
pulmonary function | 3 |
increase risk | 3 |
second messengers | 3 |
contains supplementary | 3 |
experimental hypertension | 3 |
acute tubular | 3 |
related disorders | 3 |
cirrhotic rat | 3 |
axis angiotensin | 3 |
ras actions | 3 |
vascular reparative | 3 |
damaging effects | 3 |
dilated cardiomyopathy | 3 |
gut syndrome | 3 |
normal rats | 3 |
increase ang | 3 |
central angiotensin | 3 |
renin levels | 3 |
infectious diseases | 3 |
modulatory effects | 3 |
drug administration | 3 |
motility disorders | 3 |
restore functional | 3 |
specific angiotensin | 3 |
gtp binding | 3 |
drug combination | 3 |
study group | 3 |
mouse ren | 3 |
cardiac pathology | 3 |
asian females | 3 |
organ protection | 3 |
prorenin receptors | 3 |
arb relative | 3 |
neprilysin inhibitor | 3 |
rabbit kidney | 3 |
via preventing | 3 |
embryonic development | 3 |
ultrasonic devices | 3 |
effective therapeutic | 3 |
new angiotensin | 3 |
cardiac sympathetic | 3 |
ncov sars | 3 |
ii alveolar | 3 |
inflammatory stress | 3 |
proinflammatory factors | 3 |
small intestinal | 3 |
functional angiotensin | 3 |
autophagy related | 3 |
death receptor | 3 |
systematic literature | 3 |
transformation assays | 3 |
diseased lungs | 3 |
induced pulmonary | 3 |
human recombinant | 3 |
induced ards | 3 |
human intestine | 3 |
infarcted rat | 3 |
microvascular dysfunction | 3 |
cerebral ischemia | 3 |
electrolyte absorption | 3 |
reducing brain | 3 |
dependent glucose | 3 |
worse prognosis | 3 |
early anticoagulation | 3 |
related muscle | 3 |
renin inhibitory | 3 |
associated cardiovascular | 3 |
expression changes | 3 |
mm tris | 3 |
gut disorders | 3 |
assay kit | 3 |
many countries | 3 |
mediated pressor | 3 |
chronic treatment | 3 |
ace seems | 3 |
unadjusted meta | 3 |
viral functional | 3 |
injury induced | 3 |
receptor inhibitor | 3 |
propria mesenchymal | 3 |
drug screening | 3 |
i transmembrane | 3 |
health care | 3 |
therapeutic option | 3 |
murine model | 3 |
mice carrying | 3 |
effects via | 3 |
confounding factor | 3 |
mediating cardiovascular | 3 |
homeostatic regulator | 3 |
co filter | 3 |
viral invasion | 3 |
renal pathological | 3 |
cyclic gmp | 3 |
studies indicated | 3 |
proximal tubules | 3 |
suppresses pathological | 3 |
disease ace | 3 |
also affect | 3 |
apelin receptors | 3 |
tace adam | 3 |
degrading ang | 3 |
risk alleles | 3 |
wound healing | 3 |
induce insulin | 3 |
increasing ang | 3 |
individual variation | 3 |
fibrosis development | 3 |
myocardial infarcted | 3 |
terminal catalytic | 3 |
vasodilatory effect | 3 |
two subtypes | 3 |
via several | 3 |
heme oxygenase | 3 |
increased morbidity | 3 |
aspartyl protease | 3 |
linear cascade | 3 |
potent vasoconstrictor | 3 |
lactobacillus paracasei | 3 |
exacerbates lipid | 3 |
covid infection | 3 |
gut ras | 3 |
specific brain | 3 |
ras polymorphisms | 3 |
alzheimer amyloid | 3 |
genetic susceptibility | 3 |
toxic metabolite | 3 |
podocyte biology | 3 |
peptide angiotensin | 3 |
podocytes express | 3 |
distal convoluted | 3 |
target ras | 3 |
might represent | 3 |
coronary arteries | 3 |
separate pooled | 3 |
plasma level | 3 |
podocyte membrane | 3 |
i cleavage | 3 |
randomly divided | 3 |
recovered sars | 3 |
systolic hypertension | 3 |
evidence support | 3 |
zinc metalloproteinase | 3 |
factor expression | 3 |
aii promotes | 3 |
data will | 3 |
potential effect | 3 |
aldosterone increases | 3 |
podocyte number | 3 |
also confirmed | 3 |
potentially detrimental | 3 |
diseases angiotensin | 3 |
alcoholic steatohepatitis | 3 |
related multi | 3 |
potentially lethal | 3 |
virus endocytosis | 3 |
reducing ang | 3 |
adverse clinical | 3 |
stock solution | 3 |
catalytic efficiency | 3 |
might favor | 3 |
raas inhibitors | 3 |
calcium influx | 3 |
system gender | 3 |
functional integrity | 3 |
sodium reabsorption | 3 |
serum markers | 3 |
differential downregulation | 3 |
cell granules | 3 |
vascular function | 3 |
rates among | 3 |
pathways mediating | 3 |
cardiac output | 3 |
steroidal anti | 3 |
activated prorenin | 3 |
via tgf | 3 |
support choices | 3 |
complex i | 3 |
two subdomains | 3 |
first paragraph | 3 |
patients also | 3 |
cell migration | 3 |
male mice | 3 |
genes whose | 3 |
inhibits growth | 3 |
endothelium glycocalyx | 3 |
also increase | 3 |